Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences, Inc. (RNA) Non Operating Investment Income (2020 - 2023)

Avidity Biosciences' Non Operating Investment Income history spans 4 years, with the latest figure at -$1.1 million for Q2 2023.

  • For Q2 2023, Non Operating Investment Income fell 18.44% year-over-year to -$1.1 million; the TTM value through Jun 2023 reached $320000.0, up 110.72%, while the annual FY2022 figure was -$2.5 million, 1279.67% down from the prior year.
  • Non Operating Investment Income reached -$1.1 million in Q2 2023 per RNA's latest filing, down from $1.2 million in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of $1.2 million in Q1 2023 to a low of -$1.8 million in Q1 2022.
  • Average Non Operating Investment Income over 4 years is -$242363.6, with a median of -$5000.0 recorded in 2020.
  • The largest YoY upside for Non Operating Investment Income was 511.29% in 2022 against a maximum downside of 92050.0% in 2022.
  • A 4-year view of Non Operating Investment Income shows it stood at -$5000.0 in 2020, then plummeted by 3620.0% to -$186000.0 in 2021, then soared by 511.29% to $765000.0 in 2022, then tumbled by 248.63% to -$1.1 million in 2023.
  • Per Business Quant, the three most recent readings for RNA's Non Operating Investment Income are -$1.1 million (Q2 2023), $1.2 million (Q1 2023), and $765000.0 (Q4 2022).